0DHC Stock Overview
Operates as a medical technology company in Germany, rest of Europe, North America, and Asia. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 4/6 |
Carl Zeiss Meditec AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €58.55 |
52 Week High | €123.30 |
52 Week Low | €55.00 |
Beta | 1.04 |
11 Month Change | -9.03% |
3 Month Change | -8.39% |
1 Year Change | -32.11% |
33 Year Change | -68.47% |
5 Year Change | -45.79% |
Change since IPO | 486.82% |
Recent News & Updates
Recent updates
Shareholder Returns
0DHC | GB Medical Equipment | GB Market | |
---|---|---|---|
7D | -1.3% | 7.7% | -0.4% |
1Y | -32.1% | -2.1% | 5.6% |
Return vs Industry: 0DHC underperformed the UK Medical Equipment industry which returned -2% over the past year.
Return vs Market: 0DHC underperformed the UK Market which returned 5.5% over the past year.
Price Volatility
0DHC volatility | |
---|---|
0DHC Average Weekly Movement | 6.1% |
Medical Equipment Industry Average Movement | 6.1% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 10.2% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0DHC has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0DHC's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1846 | 4,950 | Markus Weber | www.zeiss.com/meditec-ag/de/investor-relations.html?vaURL=www.zeiss.de/meditec-ag/ir |
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders.
Carl Zeiss Meditec AG Fundamentals Summary
0DHC fundamental statistics | |
---|---|
Market cap | €5.23b |
Earnings (TTM) | €203.20m |
Revenue (TTM) | €2.07b |
25.7x
P/E Ratio2.5x
P/S RatioIs 0DHC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0DHC income statement (TTM) | |
---|---|
Revenue | €2.07b |
Cost of Revenue | €927.44m |
Gross Profit | €1.14b |
Other Expenses | €935.57m |
Earnings | €203.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Dec 11, 2024
Earnings per share (EPS) | 2.27 |
Gross Margin | 55.11% |
Net Profit Margin | 9.83% |
Debt/Equity Ratio | 6.7% |
How did 0DHC perform over the long term?
See historical performance and comparison